Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9BRP0
UPID:
OVOL2_HUMAN
Alternative names:
Zinc finger protein 339
Alternative UPACC:
Q9BRP0; Q5T8B4; Q9BX22; Q9HA54; Q9Y4M0
Background:
Transcription factor Ovo-like 2, also known as Zinc finger protein 339, plays a pivotal role in maintaining epithelial lineages, suppressing epithelial-to-mesenchymal transition, and positively regulating neuronal differentiation. It is crucial for the development of primordial germ cells and plays dual functions in thermogenesis and adipogenesis to maintain energy balance.
Therapeutic significance:
Linked to Corneal dystrophy, posterior polymorphous, 1, through mutations affecting its gene, understanding the role of Transcription factor Ovo-like 2 could open doors to potential therapeutic strategies.